BRAF and melanoma: Caspase‐3/GSDME pathway is more common in targeted therapy for cachexia, and the combination of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) has been approved by the FDA for the treatment of melanoma with promising results.194